Carcinogenic risk of retained arsenic after successful treatment of acute promyelocytic leukemia with arsenic trioxide: a cause for concern?

By Firkin Frank  

Leukemia and Lymphoma, Vol. 55, Iss. 5, 2014-05 ,pp. : 977-978

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide

By Fujisawa Shinya   Ohno Ryuzo   Shigeno Kazuyuki   Sahara Naohi   Nakamura Satoki   Naito Kensuke   Kobayashi Miki   Shinjo Kaori   Takeshita Akihiro   Suzuki Yoshinari   Hashimoto Hisakuni   Kinoshita Kenji   Shimoya Masahito   Kaise Toshikazu   Ohnishi Kazunori  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 4, 2007-03 ,pp. : 485-493

Springer Publishing Company

Access to resources Recommend Favorite

Aquaporin 9, a promising predictor for the cytocidal effects of arsenic trioxide in acute promyelocytic leukemia cell lines and primary blasts

By Iriyama Noriyoshi   Yuan Bo   Yoshino Yuta   Hatta Yoshihiro   Horikoshi Akira   Aizawa Shin   Takeuchi Jin   Toyoda Hiroo  

Oncology Reports, Vol. 29, Iss. 6, 2013-06 ,pp. : 2362-2368

Spandidos Publications

Access to resources Recommend Favorite

BIBR 1532 Increases Arsenic Trioxide-mediated Apoptosis in Acute Promyelocytic Leukemia Cells: Therapeutic Potential for APL

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 13, Iss. 7, 2013-09 ,pp. : 1115-1125

Bentham Science Publishers

Access to resources Recommend Favorite

Thyroid arsenic content and papillary thyroid carcinoma arising 10 years after oral arsenic trioxide therapy for refractory acute promyelocytic leukemia

By Au Wing-yan   Lang Brian H.   Fong Bonnie M. W.   Mao Kevin J.   Tam Sidney  

Leukemia and Lymphoma, Vol. 55, Iss. 5, 2014-05 ,pp. : 1184-1185

Informa Healthcare

Access to resources Recommend Favorite